STERIS (STE) Expected to Announce Earnings on Monday

STERIS (NYSE:STE) is projected to release its Q4 2026 results after the market closes on Monday, May 11th. Analysts expect STERIS to post earnings of $2.89 per share and revenue of $1.5946 billion for the quarter. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Interested persons can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the prior year, the firm earned $2.32 EPS. STERIS’s revenue was up 9.2% on a year-over-year basis. On average, analysts expect STERIS to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

STERIS Stock Performance

NYSE STE traded down $2.12 during mid-day trading on Monday, reaching $212.28. 154,358 shares of the stock were exchanged, compared to its average volume of 771,336. The business’s 50 day moving average is $226.36 and its 200-day moving average is $244.80. STERIS has a 1 year low of $209.98 and a 1 year high of $269.44. The company has a market capitalization of $20.82 billion, a P/E ratio of 29.61 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

Insider Buying and Selling at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. GeoWealth Management LLC purchased a new position in shares of STERIS in the fourth quarter valued at approximately $306,000. Brooklyn Investment Group lifted its stake in STERIS by 36.1% in the third quarter. Brooklyn Investment Group now owns 1,222 shares of the medical equipment provider’s stock worth $302,000 after acquiring an additional 324 shares during the last quarter. Walleye Trading LLC purchased a new position in STERIS in the fourth quarter worth approximately $274,000. Voleon Capital Management LP purchased a new position in STERIS in the second quarter worth approximately $263,000. Finally, Jones Financial Companies Lllp lifted its stake in STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after acquiring an additional 349 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on STE. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Weiss Ratings cut shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $275.20.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.